TMCO5A

Summary

TMCO5A (transmembrane and coiled-coil domains 5A, HGNC:28558) is a protein-coding gene on chromosome 15q14, encoding Transmembrane and coiled-coil domain-containing protein 5A (Q8N6Q1).

Predicted to be located in membrane.

Source: NCBI Gene 145942 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 51 total
• MANE Select transcript: NM_152453

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28558
Approved symbol	TMCO5A
Name	transmembrane and coiled-coil domains 5A
Location	15q14
Locus type	gene with protein product
Status	Approved
Aliases	MGC35118
Ensembl gene	ENSG00000166069
Ensembl biotype	protein_coding
Entrez	145942

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000319669, ENST00000558148, ENST00000558158, ENST00000558625, ENST00000559502, ENST00000559813, ENST00000560653, ENST00000560841, ENST00000851987

RefSeq mRNA: 5 — MANE Select: NM_152453 NM_001330255, NM_001370735, NM_001370736, NM_001370737, NM_152453

CCDS: CCDS10046, CCDS81862

Canonical transcript exons

ENST00000319669 — 12 exons

Exon	Start	End
ENSE00001259961	37935257	37935348
ENSE00001260076	37951036	37951422
ENSE00002560723	37934640	37934694
ENSE00003464610	37942191	37942255
ENSE00003472952	37936314	37936463
ENSE00003502611	37943341	37943398
ENSE00003568892	37938158	37938229
ENSE00003589973	37937346	37937396
ENSE00003626207	37947656	37947696
ENSE00003647687	37941149	37941205
ENSE00003650901	37936847	37936970
ENSE00003657171	37941671	37941730

Expression profiles

Bgee: expression breadth broad, 66 present calls, max score 96.77.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0851 / max 78.0377, expressed in 3 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
145849	0.0851	3

Top tissues by expression

205 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	96.77	gold quality
right testis	UBERON:0004534	96.57	gold quality
sperm	CL:0000019	95.41	gold quality
testis	UBERON:0000473	93.82	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.79	gold quality
adult organism	UBERON:0007023	83.49	gold quality
buccal mucosa cell	CL:0002336	58.58	silver quality
lower lobe of lung	UBERON:0008949	58.52	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	57.44	gold quality
right uterine tube	UBERON:0001302	54.16	gold quality
tendon of biceps brachii	UBERON:0008188	53.46	gold quality
gall bladder	UBERON:0002110	52.93	gold quality
oviduct epithelium	UBERON:0004804	50.80	silver quality
upper leg skin	UBERON:0004262	50.08	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	50.04	silver quality
skin of hip	UBERON:0001554	49.82	silver quality
nasal cavity mucosa	UBERON:0001826	48.74	gold quality
body of stomach	UBERON:0001161	45.92	gold quality
cauda epididymis	UBERON:0004360	45.73	silver quality
stomach	UBERON:0000945	44.08	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
mucosa of paranasal sinus	UBERON:0005030	42.91	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
fallopian tube	UBERON:0003889	42.45	gold quality
sural nerve	UBERON:0015488	42.01	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	41.93	gold quality
vastus lateralis	UBERON:0001379	41.41	gold quality
quadriceps femoris	UBERON:0001377	41.37	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
biceps brachii	UBERON:0001507	41.13	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	32.25
E-ANND-3	yes	5.22

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1

miRNA regulators (miRDB)

18 targeting TMCO5A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-4690-5P	99.65	66.24	813
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-4710	98.61	65.96	1048
HSA-MIR-4691-5P	98.41	66.77	1343
HSA-MIR-6792-3P	98.41	66.86	1359
HSA-MIR-5088-3P	98.29	66.63	1310
HSA-MIR-3690	96.44	65.18	737
HSA-MIR-4757-3P	88.86	63.55	51

Literature-anchored findings (GeneRIF, showing 1)

• Longer survival was associated with hypomethylation at specific CpG sites (e.g. GREB1, TGIF and TOB1) and hypermethylation in other genes (e.g. TMCO5, PTPRN and GUCY2C). (PMID:21577013)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tmco5	ENSMUSG00000027355
rattus_norvegicus	Tmco5a	ENSRNOG00000005100

Paralogs (2): SMCO2 (ENSG00000165935), CCDC188 (ENSG00000234409)

Protein

Protein identifiers

Transmembrane and coiled-coil domain-containing protein 5A — Q8N6Q1 (reviewed: Q8N6Q1)

All UniProt accessions (7): A0A024R9I9, Q8N6Q1, H0YL40, H0YLD3, H0YLN2, H0YLW5, H0YMD4

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Endoplasmic reticulum membrane. Nucleus membrane.

Similarity. Belongs to the TMCO5 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N6Q1-1	1	yes
Q8N6Q1-2	2

RefSeq proteins (5): NP_001317184, NP_001357664, NP_001357665, NP_001357666, NP_689666* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026617	SMCO2/5	Family

Pfam: PF14992

UniProt features (7 total): splice variant 2, sequence conflict 2, chain 1, transmembrane region 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N6Q1-F1	85.19	0.61

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 33 (showing top): chr15q14, SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_UP, GOCC_NUCLEAR_ENVELOPE, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_NUCLEAR_MEMBRANE, GOCC_ORGANELLE_SUBCOMPARTMENT, RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN, GOCC_ORGANELLE_ENVELOPE, GSE13522_CTRL_VS_T_CRUZI_BRAZIL_STRAIN_INF_SKIN_DN, SKP2_TARGET_GENES, MIR5088_3P, GSE15659_NAIVE_VS_PTPRC_NEG_CD4_TCELL_DN, GSE15659_NAIVE_CD4_TCELL_VS_RESTING_TREG_DN, GSE15659_NAIVE_CD4_TCELL_VS_NONSUPPRESSIVE_TCELL_DN

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): endoplasmic reticulum membrane (GO:0005789), nuclear membrane (GO:0031965), nucleus (GO:0005634), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
organelle membrane	2
intracellular membrane-bounded organelle	2
binding	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
nucleus	1
nuclear envelope	1
cytoplasm	1
endomembrane system	1
cellular anatomical structure	1

Protein interactions and networks

STRING

560 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMCO5A	FAM209A	Q5JX71	705
TMCO5A	TMEM225	Q6GV28	644
TMCO5A	REDIC1	Q86WS4	628
TMCO5A	C9orf43	Q8TAL5	608
TMCO5A	SPATA16	Q9BXB7	590
TMCO5A	TMCO2	Q7Z6W1	589
TMCO5A	SPATA31G1	Q5VYM1	584
TMCO5A	C20orf173	Q96LM9	578
TMCO5A	CIMIP4	O43247	576
TMCO5A	MAGEB16	A2A368	567
TMCO5A	DHRS12	A0PJE2	543
TMCO5A	NUDT17	P0C025	540
TMCO5A	CABS1	Q96KC9	536
TMCO5A	ZFAND4	Q86XD8	531
TMCO5A	GARIN1B	Q96KD3	509

IntAct

23 interactions, top by confidence:

A	B	Type	Score
TMCO5A	C1orf216	psi-mi:“MI:0915”(physical association)	0.560
TMCO5A	TSPAN18	psi-mi:“MI:0915”(physical association)	0.560
BET1	TMCO5A	psi-mi:“MI:0915”(physical association)	0.560
VAMP5	TMCO5A	psi-mi:“MI:0915”(physical association)	0.560
GOSR2	TMCO5A	psi-mi:“MI:0915”(physical association)	0.560
TMCO5A	TMEM60	psi-mi:“MI:0915”(physical association)	0.560
	TMCO5A	psi-mi:“MI:0915”(physical association)	0.560
TMCO5A	WDR12	psi-mi:“MI:0915”(physical association)	0.400
C1orf216	TMCO5A	psi-mi:“MI:0915”(physical association)	0.000
TSPAN18	TMCO5A	psi-mi:“MI:0915”(physical association)	0.000
GOSR2	TMCO5A	psi-mi:“MI:0915”(physical association)	0.000
TMEM60	TMCO5A	psi-mi:“MI:0915”(physical association)	0.000
BET1	TMCO5A	psi-mi:“MI:0915”(physical association)	0.000
VAMP5	TMCO5A	psi-mi:“MI:0915”(physical association)	0.000
	TMCO5A	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): TMCO5A (Synthetic Lethality), TMCO5A (Two-hybrid), TMCO5A (Two-hybrid), TMCO5A (Two-hybrid), TMCO5A (Two-hybrid), TMCO5A (Two-hybrid), VAMP5 (Two-hybrid), PRH1 (Two-hybrid), WDR12 (Proximity Label-MS)

ESM2 similar proteins: A0A0A6YYL3, A2A2Z9, A6NC57, A8MYB1, A9JSR5, A9UM82, A9ZSY0, D3ZNV2, F4K1B4, G5EBL8, H3BUK9, O14043, P34606, Q01649, Q08B20, Q0VBY1, Q19UN5, Q32L59, Q4UJ75, Q501X2, Q5CZ79, Q5M7B7, Q5SQ80, Q5TYW2, Q5VUR7, Q66HB6, Q6AY08, Q7FAD5, Q7TPV2, Q7Z7B0, Q80X59, Q811D2, Q86Y13, Q86YR6, Q8IVF6, Q8N6Q1, Q8NF67, Q8WXW3, Q95JR0, Q96AA8

Diamond homologs: A8MYB1, D3ZNV2, Q32L59, Q80X59, Q8N6Q1, Q9D9D5, O02751, Q588U8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	47
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1403 predictions. Top by Δscore:

Variant	Effect	Δscore
15:37936844:CAGGC:C	acceptor_loss	1.0000
15:37936845:A:AG	acceptor_gain	1.0000
15:37936845:AG:A	acceptor_gain	1.0000
15:37936845:AGGCT:A	acceptor_gain	1.0000
15:37936846:G:GT	acceptor_gain	1.0000
15:37936846:GG:G	acceptor_gain	1.0000
15:37936846:GGCTG:G	acceptor_gain	1.0000
15:37936929:G:T	donor_gain	1.0000
15:37936953:G:GT	donor_gain	1.0000
15:37936966:GACTT:G	donor_gain	1.0000
15:37936971:G:GG	donor_gain	1.0000
15:37936979:G:GT	donor_gain	1.0000
15:37936987:G:T	donor_gain	1.0000
15:37937340:TCACA:T	acceptor_loss	1.0000
15:37937341:CACA:C	acceptor_loss	1.0000
15:37937343:CA:C	acceptor_loss	1.0000
15:37942254:GT:G	donor_gain	1.0000
15:37947697:G:GG	donor_gain	1.0000
15:37935294:GAT:G	donor_gain	0.9900
15:37935296:T:TG	donor_gain	0.9900
15:37936296:T:TA	acceptor_gain	0.9900
15:37936297:G:A	acceptor_gain	0.9900
15:37936461:GAG:G	donor_gain	0.9900
15:37936465:T:A	donor_loss	0.9900
15:37936846:GGC:G	acceptor_gain	0.9900
15:37936846:GGCT:G	acceptor_gain	0.9900
15:37936924:A:T	donor_gain	0.9900
15:37936930:A:T	donor_gain	0.9900
15:37936967:ACTT:A	donor_gain	0.9900
15:37936968:CTT:C	donor_gain	0.9900

AlphaMissense

1926 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:37951224:T:C	L286S	0.886
15:37937386:T:C	L102P	0.842
15:37951085:A:C	S240R	0.838
15:37951087:C:A	S240R	0.838
15:37951087:C:G	S240R	0.838
15:37951159:G:C	R264S	0.829
15:37951159:G:T	R264S	0.829
15:37941702:T:C	L159P	0.826
15:37951109:T:C	F248L	0.825
15:37951111:C:A	F248L	0.825
15:37951111:C:G	F248L	0.825
15:37951117:T:A	N250K	0.810
15:37951117:T:G	N250K	0.810
15:37936411:G:C	A30P	0.793
15:37951171:G:C	W268C	0.792
15:37951171:G:T	W268C	0.792
15:37951140:T:G	L258R	0.791
15:37951176:T:C	L270P	0.783
15:37936969:T:C	L88P	0.779
15:37951176:T:A	L270H	0.778
15:37941198:T:C	L146P	0.774
15:37936353:A:C	K10N	0.773
15:37936353:A:T	K10N	0.773
15:37936382:T:C	L20P	0.762
15:37936352:A:T	K10I	0.759
15:37941714:A:C	Q163P	0.743
15:37941716:G:C	A164P	0.740
15:37941730:G:C	K168N	0.734
15:37941730:G:T	K168N	0.734
15:37951140:T:A	L258Q	0.733

dbSNP variants (sampled 300 via entrez): RS1000030387 (15:38001072 A>T), RS1000053992 (15:37961568 C>T), RS1000081242 (15:37955745 C>G), RS1000119165 (15:37960184 CT>C), RS1000155534 (15:38036506 A>T), RS1000192168 (15:37994520 A>G), RS1000195090 (15:37948081 C>A), RS1000222217 (15:37964907 A>G), RS1000224077 (15:38029276 C>A), RS1000247387 (15:37987904 A>C,T), RS1000257978 (15:38023199 T>C), RS1000284542 (15:38007373 G>A), RS1000290646 (15:37950329 C>G,T), RS1000360936 (15:38030713 A>G), RS1000362092 (15:37936027 G>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST002829_8	Urate levels in overweight individuals	2.000000e-07
GCST003875_15	Gut microbiota (bacterial taxa)	4.000000e-08
GCST005348_37	Total body bone mineral density	5.000000e-10
GCST005795_1	Femoral neck bone mineral density	2.000000e-08
GCST005796_25	Lumbar spine bone mineral density	3.000000e-07
GCST006041_11	Major depressive disorder	1.000000e-08
GCST009391_1977	Metabolite levels	6.000000e-06
GCST009548_4	NASH resolution in nonalcoholic steatohepatitis	6.000000e-06
GCST010989_70	Body size at age 10	4.000000e-08

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0007874	gut microbiome measurement
EFO:0007883	taxonomic microbiome measurement
EFO:0007785	femoral neck bone mineral density
EFO:0007701	spine bone mineral density
EFO:0008534	tryptophan measurement
EFO:0009785	remission
EFO:0009819	comparative body size at age 10, self-reported

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
propionaldehyde	decreases expression	1
bisphenol A	decreases methylation	1
2-palmitoylglycerol	increases expression	1
Benzo(a)pyrene	increases methylation	1
Caffeine	decreases phosphorylation	1
Tobacco Smoke Pollution	decreases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer